- |||||||||| Trial primary completion date: Thyroid Disease Serum Repository (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=1000, Suspended, Trial primary completion date: May 2016 --> May 2017
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Radioactive Iodide Therapy for Pediatric Graves' Disease (clinicaltrials.gov) - Jun 13, 2016
P2, N=22, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed | N=300 --> 22 | Trial primary completion date: Aug 2018 --> Jun 2016
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion, Trial primary completion date: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - May 6, 2016 P4, N=31, Completed, Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Apr 14, 2016 P1, N=111, Active, not recruiting, Recruiting --> Completed Trial primary completion date: Dec 2015 --> Apr 2016
- |||||||||| Trial completion, Enrollment change: The Diagnostic Value of Shear Wave Elastography (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=308, Completed, Trial primary completion date: Dec 2015 --> Apr 2016 Recruiting --> Completed | N=400 --> 308
- |||||||||| Trial suspension: Thyroid Disease Serum Repository (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=1000, Suspended, Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Suspended
- |||||||||| Iclusig (ponatinib) / Takeda
Enrollment change, Trial termination, Trial primary completion date: Ponatinib for Advanced Medullary Thyroid Cancer (clinicaltrials.gov) - Mar 18, 2016 P2, N=3, Terminated, N=31 --> 3 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Dec 2015; Recruiting halted prematurely and will not resume. New study to open soon.
- |||||||||| MIKA Diclofenac Spray Gel (diclofenac spraygel) / Nogra Pharma
Trial completion, Trial primary completion date: Adjuvant Treatment of Graves (clinicaltrials.gov) - Feb 24, 2016 P4, N=65, Completed, Not yet recruiting --> Recruiting | Trial primary completion date: May 2013 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Feb 2016
- |||||||||| Enrollment closed, Trial primary completion date: Low Level Laser Therapy for Autoimmune Thyroiditis (clinicaltrials.gov) - Feb 23, 2016
P2/3, N=43, Active, not recruiting, N=300 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015
- |||||||||| Trial completion, Trial primary completion date, Surgery: The Efficacy and Safety of Thunderbeat in Thyroid Surgery (clinicaltrials.gov) - Feb 16, 2016
P=N/A, N=50, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Dec 2015
- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date: Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients (clinicaltrials.gov) - Jan 26, 2016
P2, N=35, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=15 --> 35 | Trial primary completion date: Feb 2016 --> Jan 2017
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: Tocilizumab Treatment in Graves (clinicaltrials.gov) - Jan 20, 2016 P3, N=32, Completed, Recruiting --> Completed | N=458 --> 327 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2015
- |||||||||| Phase classification, Trial primary completion date: Remission Induction and Sustenance in Graves' Disease 2 (clinicaltrials.gov) - Dec 31, 2015
P=N/A, N=250, Active, not recruiting, Trial primary completion date: Dec 2015 --> Dec 2016 Phase classification: P4 --> P=N/A | Trial primary completion date: Oct 2015 --> Oct 2017
- |||||||||| Trial primary completion date: Polymorphisms in the Vitamin D System and Health (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=9700, Active, not recruiting, Recruiting --> Active, not recruiting | N=500 --> 193 Trial primary completion date: Oct 2015 --> Jul 2016
- |||||||||| dexamethasone / Generic mfg.
Trial completion, Enrollment change, Surgery: Dexamethasone and Wound Healing After Thyroid Surgery (clinicaltrials.gov) - Nov 30, 2015 P=N/A, N=220, Completed, Trial primary completion date: Oct 2015 --> Jul 2016 Recruiting --> Completed | N=150 --> 220
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Enrollment change, Combination therapy, Surgery, Metastases: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 9, 2015 P1, N=6, Completed, N=112 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Jul 2012; Safety concerns Active, not recruiting --> Completed | N=24 --> 6
|